$-0.02 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO)

March 22, 2018 - By Clifton Ray

 $ 0.02 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO)
Investors sentiment increased to 1.32 in Q3 2017. Its up 0.23, from 1.09 in 2017Q2. It increased, as 10 investors sold AVEO Pharmaceuticals, Inc. shares while 12 reduced holdings. 14 funds opened positions while 15 raised stakes. 59.90 million shares or 5.78% less from 63.58 million shares in 2017Q2 were reported.
Prelude Mgmt Ltd Liability stated it has 0.03% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Edge Wealth Mgmt Limited Com holds 10,000 shares. California Pub Employees Retirement Sys reported 33,400 shares. Northern holds 206,033 shares or 0% of its portfolio. Cannell Peter B And Inc holds 0.01% or 109,875 shares. Sanctuary Wealth Advsr Ltd Com owns 0.01% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 2,042 shares. Excalibur Mgmt invested 0.03% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Raymond James Financial Svcs Advsrs stated it has 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Citigroup invested in 2,670 shares. Evercore Wealth Ltd Limited Liability Company holds 0.02% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 168,414 shares. 11,325 were reported by Cubist Systematic Strategies Ltd. Pnc Services Grp invested in 0% or 14,000 shares. Nea Mgmt Limited Liability Company owns 16.36 million shares. Vanguard Grp holds 4.26M shares. State Street, a Massachusetts-based fund reported 92,375 shares.

Analysts expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report $-0.02 EPS on March, 28.They anticipate $0.09 EPS change or 81.82 % from last quarter’s $-0.11 EPS. After having $-0.02 EPS previously, AVEO Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock increased 3.09% or $0.09 during the last trading session, reaching $3. About 2.21M shares traded or 28.28% up from the average. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has declined 16.67% since March 22, 2017 and is downtrending. It has underperformed by 33.37% the S&P500.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Ratings Coverage

Among 3 analysts covering AVEO Pharmaceuticals (NASDAQ:AVEO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AVEO Pharmaceuticals has $7 highest and $200 lowest target. $5.67’s average target is 89.00% above currents $3 stock price. AVEO Pharmaceuticals had 13 analyst reports since March 30, 2016 according to SRatingsIntel. Piper Jaffray maintained it with “Buy” rating and $5.0 target in Thursday, October 5 report. The rating was maintained by FBR Capital on Tuesday, March 13 with “Buy”. The rating was initiated by FBR Capital with “Outperform” on Wednesday, March 30. FBR Capital maintained AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on Tuesday, January 16 with “Buy” rating. The firm has “Buy” rating by FBR Capital given on Monday, February 12. Piper Jaffray maintained AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) rating on Wednesday, August 9. Piper Jaffray has “Buy” rating and $3.5000 target. The firm has “Overweight” rating given on Thursday, May 19 by Piper Jaffray. On Monday, June 26 the stock rating was maintained by FBR Capital with “Buy”. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) earned “Buy” rating by FBR Capital on Thursday, December 7. The rating was upgraded by Piper Jaffray to “Buy” on Monday, August 28.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $462.46 million. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

Another recent and important AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) news was published by Zacks.com which published an article titled: “AVEO Pharmaceuticals (AVEO) Q4 Loss Wider, Revenues Miss March 13, 2018” on March 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.